Selected Start-Ups (7/01)
Executive SummaryIn Vivo summarizes the technologies of these recently founded companies: Aviva Antibody Corp. will produce monoclonal antibodies for the post-genomics research efforts of future corporate partners. Corus Pharma Inc. will focus on the rapid clinical development and regulatory approval of small-molecule drugs for sleep disorders and respiratory diseases. Isogenica Ltd.'s Covalent Display, is an in vitro library technology for rapidly identifying polypeptides with high affinity and specificity for any given target. Liposonix Inc. will use high-intensity ultrasound to remove unwanted subcutaneous fat. Scienion AG will develop "future-oriented" biochips for use in genomics and proteomics research, DNA diagnostics and the drug discovery and development. Xcellsyz Ltd.'s platform for drug discovery and development is based on conditionally immortalized cell lines that retain many of the properties of primary cells.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.